This site is intended for healthcare professionals
News

CHMP recommends Fetcroja, intended for the treatment of infections due to aerobic Gram-negative organisms .- Shionogi

Read time: 1 mins
Published:4th Mar 2020
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Fetcroja, intended for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. The applicant for this medicinal product is Shionogi B.V. Fetcroja will be available as a 1 g powder for concentrate for solution for infusion. The active substance of Fetcroja is cefiderocol, an antibacterial for systemic use (ATC code: J01DI04). It is a siderophore cephalosporin which acts by inhibiting the formation of the peptidoglycan, an important component of the bacterial cell wall. The benefits with Fetcroja are its ability to treat aerobic Gram-negative infections effectively. The most common side effects are diarrhoea, vomiting, nausea and cough.
Condition: Infectious Diseases/UTI
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.